PharmaTimes January 13, 2025
Survey finds AI to enhance productivity and cut costs in the next 12 months
AI is poised to significantly lower pharmaceutical R&D costs through efficient drug discovery, optimised clinical trials, and predictive data analysis, according to a GlobalData survey.
The leading data and analytics company’s report, “The State of the Biopharmaceutical Industry – 2025,” highlights AI’s potential to boost productivity and cut costs in the coming year.
Urte Jakimaviciute, Senior Director of Market Research and Strategic Intelligence in the healthcare division at GlobalData, emphasised the importance of improving R&D productivity.
“Enhancing productivity in pharmaceutical R&D is fundamental as it accelerates the development of new drugs, enabling companies to innovate more effectively, respond to emerging medical needs, and maintain a competitive...
Today's Sponsors
Today's Sponsor